Results for intravenous translation from French to Dutch

busulfan (intravenous use)
busulfan (intravenous use)

intravenous infusion 130mg/ml 1
- intravenous infusion - 130mg/ml -1

intravenous conditioning treatment prior to hematopoietic progenitor cell transplantation
intravenous conditioning treatment prior to hematopoietic progenitor cell transplantation

denmark droppy : the computer controlled intravenous 'drip feed'
denemarken droppy : the computer controlled intravenous 'drip feed' (droppy : het computergestuurd intraveneus infuus)

clinical investigation of human normal immunoglobulin for intravenous administration (ivig)
clinical investigation of human normal immunoglobulin for intravenous administration (ivig)

core spc for human normal immunoglobulin for intravenous administration (ivig) adoptée en juin 2000
aangenomen in juni 2000

clinical investigation of human anti-d immunoglobulin and human anti-d immunoglobulin for intravenous use
richtsnoeren clinical investigation of human anti-d immunoglobulin and human anti-d immunoglobulin for intravenous use

core spc for human and anti-d immunoglobulin for intravenous and/or intramuscular use adoptée en juin 2000
aangenomen in juni 2000

core spc for human anti-d immunoglobulin transmise pour consultation en juin 1999 and human anti-d immunoglobulin for intravenous use
core spc for human anti-d immunoglobulin and human anti-d immunoglobulin for intravenous use

core summary of product characteristics for hepatitis b immunoglobulin revision of core summary of product characteristics for human normal immunoglobulin for intravenous use – addition of indication for treatment of parvovirus b19 infection revision of core summary of product characteristics for human plasma derived factor vii products and human plasma prothrombin complex revision of core summary of product characteristics for factor viii inhibitor bypassing fraction warning on transmissible agents for patient leaflets and summary of product characteristics revision of core summary of product characteristics for human anti-d immunoglobulin for intravenous and/ or intramuscular use (cpmp/ bpwg/ 574/ 99)
core summary of product characteristics for hepatitis b immunoglobulin revision of core summary of product characteristics for human normal immunoglobulin for intravenous use – addition of indication for treatment of parvovirus b19 infection revision of core summary of product characteristics for human plasma derived factor vii products and human plasma prothrombin complex revision of core summary of product characteristics for factor viii inhibitor bypassing fraction warning on transmissible agents for patient leaflets and summary of product characteristics revision of core summary of product characteristics for human anti-d immunoglobulin for intravenous and/or intramuscular use (cpmp/bpwg/574/99)